Rema Raman, PhD

Rema Raman is a Professor of Neurology at Keck School of Medicine of USC and the Director of the Biostatistics Section and the Recruitment, Engagement, and Retention (RER) Section at the USC Alzheimer’s Therapeutic Research Institute (ATRI). Dr. Raman serves as co-lead of several key units within the NIH-funded Alzheimer’s Clinical Trials Consortium, including Biostatistics, Recruitment, Engagement & Retention (RER), and Alzheimer’s Clinical Trials – Education, Engagement, Access, and Accountability (ACT-E2A2).
Dr. Raman has focused her academic career in the design, conduct and analysis of clinical trials in neurology. She has extensive experience as a collaborative biostatistician and clinical trialist, serving in the leadership team of several highly integrated and interdisciplinary research programs conducting clinical research in Alzheimer¹s disease, stroke, post-traumatic stress disorder, and traumatic brain injury. Her primary statistical research interests are in innovative trial design, advanced statistical methods for missing and correlated data, centralized statistical monitoring, and strategies to improve participant recruitment and retention.
Dr. Raman is committed to the effective teaching of biostatistics and clinical trial methodology to undergraduate, graduate, and medical students, postdoctoral fellows and other clinical researchers. She is co-director of the NIA- and Alzheimer’s Association- funded Institute of Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD) program that aims to educate and train the next generation of clinical trial researchers and future principal investigators in the field of Alzheimer’s Disease and Related Disorders clinical trials research.

• University of Illinois at Chicago, Chicago, IL — Ph.D. — Biostatistics
• University of Iowa, Iowa City, IA — M.S. — Biostatistics
• Bowling Green State University, Bowling Green, OH — M.A — Scientific Computation (Applied Mathematics)

• Clinical Biostatistics
• Clinical Trials
• Neurology
• Alzheimer's Disease
• Recruitment and Retention science

• Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial. Lancet. 2026 Aug 01; 408(10553):417-429.. View in PubMed
• Recent Cochrane review has serious flaws: A perspective of clinicians and researchers from around the world. Alzheimers Dement. 2026 Jul; 22(7):e71696.. View in PubMed
• Improving the clinical trial landscape for patients with atypical variants of Alzheimer’s disease: a call to action. Alzheimers Dement. 2026 Jun; 22(6):e71521.. View in PubMed
• A scoping review of dementia education programs for Chinese, Japanese, Korean, Filipino, and Vietnamese communities. Alzheimers Dement (Amst). 2026 Apr-Jun; 18(2):e70295.. View in PubMed
• Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults. J Prev Alzheimers Dis. 2026 May; 13(5):100543.. View in PubMed
• Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: Implications for secondary prevention trials. Alzheimers Dement. 2026 Apr; 22(4):e71366.. View in PubMed
• Evaluating evidence-based recruitment strategies for Alzheimer’s disease and related dementias clinical trial research: A literature review. J Prev Alzheimers Dis. 2026 May; 13(5):100532.. View in PubMed
• Amyloid Imaging and APOE Genotype Disclosure and Short-Term Psychological Distress. JAMA Netw Open. 2026 Mar 02; 9(3):e263845.. View in PubMed
• The relationships between ethnoracial identity, Aβ positivity, APOEε4, and medial temporal lobe tau PET. Alzheimers Dement. 2026 Mar; 22(3):e71226.. View in PubMed
• Uniform Amyloid Thresholds Across Populations. JAMA Neurol. 2026 Mar 01; 83(3):296-299.. View in PubMed
• Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults. Alzheimers Dement. 2026 Feb; 22(2):e71225.. View in PubMed
• Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration. J Prev Alzheimers Dis. 2026 Mar; 13(3):100486.. View in PubMed
• Divergent patterns of cognitive decline in preclinical Alzheimer’s disease: implications for secondary prevention trials. medRxiv. 2026 Jan 21.. View in PubMed
• Prevalence of frailty and its association with cognition in preclinical Alzheimer’s disease: a cross-sectional analysis of baseline data from the A4 study. Age Ageing. 2026 Jan 03; 55(1).. View in PubMed
• Alzheimer’s disease polygenic risk in early- and late-onset Alzheimer’s disease. Alzheimers Dement. 2026 01; 22(1):e71066.. View in PubMed
• Current evidence of randomized clinical trials on hospice-eligible patients with agitation and dementia: A narrative review. Palliat Support Care. 2025 Nov 27; 23:e209.. View in PubMed
• Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer’s Disease. bioRxiv. 2025 Nov 24.. View in PubMed
• Voiceprints of cognitive impairment: analyzing digital voice for early detection of Alzheimer’s and related dementias. NPJ Dement. 2025; 1(1):35.. View in PubMed
• Response to “Brain Amyloid and Cognitive Decline in Late-Life Depression”. Am J Geriatr Psychiatry. 2026 Feb; 34(2):258-261.. View in PubMed
• Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites. Alzheimers Res Ther. 2025 10 14; 17(1):222.. View in PubMed
• Employment, volunteering, and health-related resource use in pre-symptomatic AD: Results from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study. Alzheimers Dement. 2025 10; 21(10):e70641.. View in PubMed
• Evaluating the Science of Diversity in Clinical Trials: Design and Goals of an American Heart Association Strategic Focused Research Network. J Am Heart Assoc. 2025 Oct 07; 14(19):e041831.. View in PubMed
• Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer’s disease. Alzheimers Dement. 2025 09; 21(9):e70702.. View in PubMed
• Accelerated Cognitive Decline in Late Life Depression: The Role of Amyloid-β, Cortico-Limbic Volume, and White Matter Hyperintensities. Am J Geriatr Psychiatry. 2026 02; 34(2):183-194.. View in PubMed
• Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial. JAMA. 2025 08 26; 334(8):681-691.. View in PubMed
• Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab. Alzheimers Dement (Amst). 2025 Jul-Sep; 17(3):e70164.. View in PubMed
• Modernizing diagnosis of Alzheimer’s disease: A review of global trends and Asia-specific perspectives. Alzheimers Dement. 2025 08; 21(8):e70536.. View in PubMed
• Effects of a modular telehealth intervention on comorbid conditions in service members with mild traumatic brain injury. Front Neurol. 2025; 16:1594748.. View in PubMed
• Racial Climate on Willingness to Participate in Clinical Research. J Racial Ethn Health Disparities. 2025 Jul 07.. View in PubMed
• Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER. Alzheimers Dement. 2025 07; 21(7):e70216.. View in PubMed
• Five years of the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD). Alzheimers Dement. 2025 07; 21(7):e70441.. View in PubMed
• Establishing tau-PET cut-points for cognitive diagnosis with 18 F-PI-2620 in a multi-ethnoracial cohort. Imaging Neurosci (Camb). 2025; 3.. View in PubMed
• Advancing the science of recruitment for Alzheimer’s clinical trials: Challenges and opportunities. J Prev Alzheimers Dis. 2025 Aug; 12(7):100230.. View in PubMed
• Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid. Neurology. 2025 Jun 24; 104(12):e213775.. View in PubMed
• Sex Differences in the Neurovascular Health of Aging Adults. Stroke. 2025 Aug; 56(8):2177-2189.. View in PubMed
• Challenges and opportunities for novel combination therapies in Alzheimer’s disease: a report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2025 Jun; 12(6):100163.. View in PubMed
• Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer’s Disease: Comparison of the LEADS and ADNI Cohorts. Ann Neurol. 2025 08; 98(2):236-248.. View in PubMed
• Heterogeneous clinical phenotypes of sporadic early-onset Alzheimer’s disease: a neuropsychological data-driven approach. Alzheimers Res Ther. 2025 02 06; 17(1):38.. View in PubMed
• Disclosure of elevated amyloid status is not associated with long-term suicidality in a preclinical AD trial. Alzheimers Dement. 2025 02; 21(2):e14623.. View in PubMed
• Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement. 2025 01; 21(1):e14202.. View in PubMed
• Achieving Inclusion in Pharmacological Clinical Trials for Alzheimer’s Disease. Curr Top Behav Neurosci. 2025; 69:229-242.. View in PubMed
• Artificial intelligence-enabled safety monitoring in Alzheimer’s disease clinical trials. J Prev Alzheimers Dis. 2025 Jan; 12(1):100002.. View in PubMed
• Differential associations of neighborhood disadvantage, race/ethnicity, and cognitive status with experiences of psychosocial distress in the HABS-HD cohort. Alzheimers Dement. 2025 01; 21(1):e14257.. View in PubMed
• Cortico-limbic volume abnormalities in late life depression are distinct from β amyloid and white matter pathologies. Mol Psychiatry. 2025 Apr; 30(4):1267-1276.. View in PubMed
• Anxiety in late-life depression: Associations with brain volume, amyloid beta, white matter lesions, cognition, and functional ability. Int Psychogeriatr. 2024 Nov; 36(11):1009-1020.. View in PubMed
• Anxiety in late-life depression is associated with poorer performance across multiple cognitive domains. J Int Neuropsychol Soc. 2024 11; 30(9):807-811.. View in PubMed
• Derivation of Indices of Cognitive Change Among Hispanic Adults and Elders. JAMA Netw Open. 2024 09 03; 7(9):e2431180.. View in PubMed
• The Alzheimer’s Disease Neuroimaging Initiative Clinical Core. Alzheimers Dement. 2024 10; 20(10):7361-7368.. View in PubMed
• A Protocol for the Inclusion of Minoritized Persons in Alzheimer Disease Research From the ADNI3 Diversity Taskforce. JAMA Netw Open. 2024 08 01; 7(8):e2427073.. View in PubMed
• The 2022 symposium on dementia and brain aging in low- and middle-income countries: Highlights on research, diagnosis, care, and impact. Alzheimers Dement. 2024 06; 20(6):4290-4314.. View in PubMed
• Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial. Alzheimers Dement. 2024 06; 20(6):3827-3838.. View in PubMed
• The AUstralian multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention study (AU-ARROW): A study protocol for a single-blind, multi-site, randomized controlled trial. Alzheimers Dement (N Y). 2024 Apr-Jun; 10(2):e12466.. View in PubMed
• Anxiety in late-life depression: Associations with brain volume, amyloid beta, white matter lesions, cognition, and functional ability. Int Psychogeriatr. 2024 11; 36(11):1009-1020.. View in PubMed
• Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurol Clin Pract. 2024 Apr; 14(2):e200265.. View in PubMed
• Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer’s Disease Randomized Controlled Trial. J Prev Alzheimers Dis. 2024; 11(4):874-880.. View in PubMed
• The AlzMatch Pilot Study – Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer’s Disease Trials. J Prev Alzheimers Dis. 2024; 11(5):1435-1444.. View in PubMed
• Estimating Socio-Economic Status for Alzheimer’s Disease Trials. J Prev Alzheimers Dis. 2024; 11(5):1418-1425.. View in PubMed
• Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study. J Prev Alzheimers Dis. 2024; 11(4):814-822.. View in PubMed
• Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer’s Disease Clinical Trials; A Rapid Review. J Prev Alzheimers Dis. 2024; 11(6):1647-1672.. View in PubMed
• Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies. J Prev Alzheimers Dis. 2024; 11(4):802-813.. View in PubMed
• Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer’s Disease. J Prev Alzheimers Dis. 2024; 11(4):823-830.. View in PubMed
• Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4. J Prev Alzheimers Dis. 2024; 11(4):831-837.. View in PubMed
• Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer’s Disease. J Prev Alzheimers Dis. 2024; 11(4):869-873.. View in PubMed
• Views and Perceptions of Amyloid Imaging in a Preclinical Alzheimer’s Disease Trial. J Prev Alzheimers Dis. 2024; 11(6):1563-1571.. View in PubMed
• Relationship of Hoarding and Depression Symptoms in Older Adults. Am J Geriatr Psychiatry. 2024 04; 32(4):497-508.. View in PubMed
• Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimers Dement. 2024 02; 20(2):1214-1224.. View in PubMed
• Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease. Ann Neurol. 2024 02; 95(2):288-298.. View in PubMed
• Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER). Alzheimers Dement. 2024 02; 20(2):769-782.. View in PubMed
• Ascertainment and Statistical Issues for Randomized Trials of Cardiovascular Interventions for Cognitive Impairment and Dementia. Hypertension. 2024 01; 81(1):45-53.. View in PubMed
• Evaluation of Neighborhood-Level Disadvantage and Cognition in Mexican American and Non-Hispanic White Adults 50 Years and Older in the US. JAMA Netw Open. 2023 08 01; 6(8):e2325325.. View in PubMed
• Trial of Solanezumab in Preclinical Alzheimer’s Disease. N Engl J Med. 2023 09 21; 389(12):1096-1107.. View in PubMed
• Protective effects of sleep duration and physical activity on cognitive performance are influenced by β-amyloid and brain volume but not tau burden among cognitively unimpaired older adults. Neuroimage Clin. 2023; 39:103460.. View in PubMed
• Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment. Alzheimers Res Ther. 2023 05 02; 15(1):88.. View in PubMed
• Safety and tolerability of lumbar puncture for the evaluation of Alzheimer’s disease. Alzheimers Dement (Amst). 2023 Apr-Jun; 15(2):e12431.. View in PubMed
• The Nairobi Declaration-Reducing the burden of dementia in low- and middle-income countries (LMICs): Declaration of the 2022 Symposium on Dementia and Brain Aging in LMICs. Alzheimers Dement. 2023 Mar 11.. View in PubMed
• Natural cubic splines for the analysis of Alzheimer’s clinical trials. Pharm Stat. 2023 May-Jun; 22(3):508-519.. View in PubMed
• Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer’s Disease. J Alzheimers Dis. 2023; 92(1):95-107.. View in PubMed
• Attitudes about involvement in hypothetical clinical trial protocols in Mexican and Mexican-American at risk for autosomal dominant Alzheimer’s disease. Alzheimers Res Ther. 2022 11 15; 14(1):173.. View in PubMed
• Improving generalizability and study design of Alzheimer’s disease cohort studies in the United States by including under-represented populations. Alzheimers Dement. 2023 04; 19(4):1549-1557.. View in PubMed
• What Should the Goals Be for Diverse Recruitment in Alzheimer Clinical Trials? JAMA Neurol. 2022 11 01; 79(11):1097-1098. Grill JD , Sperling RA, Raman R . View in PubMed
• The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer’s disease. Alzheimers Dement. 2023 04; 19(4):1227-1233.. View in PubMed
• Early-stage Alzheimer disease: getting trial-ready. Nat Rev Neurol. 2022 07; 18(7):389-399.. View in PubMed
• Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2022 12; 18(12):2603-2613.. View in PubMed
• Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer’s Symposium. Alzheimers Dement. 2022 09; 18(9):1677-1686.. View in PubMed
• Alzheimer’s disease research progress in the Mediterranean region: The Alzheimer’s Association International Conference Satellite Symposium. Alzheimers Dement. 2022 10; 18(10):1957-1968.. View in PubMed
• Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial. Sci Rep. 2022 01 25; 12(1):1346.. View in PubMed
• Enhanced Association of Tau Pathology and Cognitive Impairment in Mild Cognitive Impairment Subjects with Behavior Symptoms. J Alzheimers Dis. 2022; 87(2):557-568.. View in PubMed
• Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report. J Prev Alzheimers Dis. 2022; 9(3):388-392.. View in PubMed
• Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. Sleep Adv. 2021; 2(1):zpab015.. View in PubMed
• Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. JAMA Netw Open. 2021 07 01; 4(7):e2114364.. View in PubMed
• Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. Alzheimers Dement (N Y). 2021; 7(1):e12135.. View in PubMed
• Impact of the COVID-19 pandemic on statistical design and analysis plans for multidomain intervention clinical trials: Experience from World-Wide FINGERS. Alzheimers Dement (N Y). 2021; 7(1):e12143.. View in PubMed
• Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. JAMA Neurol. 2021 03 01; 78(3):293-301.. View in PubMed
• The Impact of Amyloid Burden and APOE on Rates of Cognitive Impairment in Late Life Depression. J Alzheimers Dis. 2021; 80(3):991-1002.. View in PubMed
• The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program. J Prev Alzheimers Dis. 2021; 8(3):286-291.. View in PubMed
• Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. JAMA Neurol. 2020 12 01; 77(12):1504-1513.. View in PubMed
• Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimers Dement (Amst). 2020; 12(1):e12118.. View in PubMed
• Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA Neurol. 2020 09 01; 77(9):1099-1109.. View in PubMed
• World-Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020 07; 16(7):1078-1094.. View in PubMed
• Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer’s Disease Neuroimaging Initiative Depression Project. Biol Psychiatry. 2021 04 15; 89(8):757-765.. View in PubMed

• Aisen, Paul